Arpino G et al. Estrogen receptor positive (ER+), progesterone receptor negative (PgR) breast cancer: New insights into molecular mechanisms and clinical implications. Breast Cancer Res Treat 2004;Abstract 105.

Basso U et al. Older age limits the use of adjuvant chemotherapy according to all negative risk factors in early breast cancer patients. Proc ASCO 2004;Abstract 8159.

Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract

Berliere M et al. LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen. Eur J Cancer 2004;40(12):1855-61. Abstract

Berry DA et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, nodepositive breast cancer: 20-year experience of the CALGB and U.S. Breast Intergroup. Breast Cancer Res Treat 2004;Abstract 29.

Bertelli G et al. Intergroup exemestane study: Results of the endometrial subprotocol. Breast Cancer Res Treat 2004;Abstract 402.

Biganzoli L et al. Adjuvant chemotherapy in elderly patients with breast cancer: A survey of the Breast International Group (BIG). Ann Oncol 2004;15(2):207-10. Abstract

Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;Abstract 3.

Boccardo F et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. J Clin Oncol 2001;19(22):4209-15. Abstract

Bonadonna G et al. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol 2004;22(9):1614-20. Abstract

Bonneterre J et al. Long-term cardiac followup in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 2004;22(15):3070-9. Abstract

Brain EGC et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+≤3) breast cancer (BC) patients (pts): First analysis of toxicity. Proc ASCO 2004;Abstract 617.

Buzdar AU; ATAC trialists’ group. ‘Arimidex’ (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer — efficacy overview. J Steroid Biochem Mol Biol 2003;86(3-5):399-403. Abstract

Cameron DA et al. Does everyone need letrozole after 5 years tamoxifen and breast conservation? Breast Cancer Res Treat 2004;Abstract 108.

Carlson RW et al. Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/ metastatic breast cancer. Breast Cancer Res Treat 2004;Abstract 6052.

Castiglione-Gertsch M et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph nodenegative breast cancer: A randomized trial. J Natl Cancer Inst 2003;95(24):1833-46. Abstract

Citron ML et al. Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Coleman R et al. Association between prior chemotherapy and the adverse event (AE) profile of adjuvant anastrozole (A) or tamoxifen (T): A retrospective analysis from the ATAC trial. Proc ASCO 2004;Abstract 767.

Coleman RE et al. Intergroup exemestane study: 1 year results of the bone subprotocol. Breast Cancer Res Treat 2004;Abstract 401.

Colleoni M et al. Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with nodepositive (N+), early stage breast cancer: First results of International Breast Cancer Study Group Trial 13-93. Proc ASCO 2004;Abstract 532.

Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081- 92. Abstract

Coombes RC et al. The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. Breast Cancer Res Treat 2004;Abstract 3.

de Haes H et al; Zoladex Early Breast Cancer Research Association Trialists Group. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: The Zoladex Early Breast Cancer Research Association Trialists Group. J Clin Oncol 2003;21(24):4510-6. Abstract

Delozier T et al. Reducing dose density in adjuvant chemotherapy (C) is detrimental in early breast cancer (EBC). A review of 872 adjuvant treatments in Centre François Baclesse. Proc ASCO 2004;Abstract 583.

Distler W et al. Impact of age on the gynecologic adverse event (AE) profile of anastrozole (A) or tamoxifen (T) in the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2004;Abstract 770.

Dowsett M, on behalf of the ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (Anastrozole, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;83(Suppl 1):7;Abstract 4.

Duffy S et al. The ATAC adjuvant breast cancer trial in postmenopausal women: Baseline endometrial subprotocol data. BJOG 2003;110(12):1099-106. Abstract

Duric V et al. Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). Proc ASCO 2004;Abstract 787.

Emens LA, Davidson NE. Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res 2003;9(1 Pt 2):486S-94S. Abstract

Fallowfield LJ et al. Intergroup exemestane study: Results of the quality of life sub-protocol. Breast Cancer Res Treat 2004;Abstract 4.

Faneyte IF et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 2004;10(13):4457- 63. Abstract

Fogelman I et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003;14(12):1001-6. Abstract

Fumoleau P et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, nodepositive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003;21(2):298-305. Abstract

Ghani F et al. Confirmation of C9741 intergroup results in a prospectively randomized trial comparing dose-intense chemotherapy with G-CSF support to 3-weekly chemotherapy for adjuvant therapy of nodal-positive (1-3 LN) breast cancer: Longitudinal CA 27.29 results indicate higher decay of minimal residual disease in the dose-dense arm. Proc ASCO 2004;Abstract 805.

Gnant M et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial. Breast Cancer Res Treat 2002;Abstract 12.

Gnant M et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen — bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Breast Cancer Res Treat 2004;Abstract 6.

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract

Henderson IC et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer. J Clin Oncol 2003;21(6):976-83. Abstract

Howell A et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Howell A et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer — updated efficacy results based on a median follow-up of 5 years. Breast Cancer Res Treat 2004;Abstract 1.

Hudis CA, Schmitz N. Dose-dense chemotherapy in breast cancer and lymphoma. Semin Oncol 2004;31(3 Suppl 8):19-26. Abstract

Jakesz R et al; Austrian Breast and Colorectal Cancer Study Group Trial 5. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer — Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20(24):4621-7. Abstract

Jakesz R et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004;Abstract 2.

Jonat W et al; Zoladex Early Breast Cancer Research Association Study. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002;20(24):4628-35. Abstract

Kaufman PA et al. Randomized double-blind phase 2 study evaluating same-day vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with early stage and advanced breast cancer. Breast Cancer Res Treat 2004;Abstract 1054.

Kaufmann M et al; Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists’ Group. Survival analyses from the ZEBRA study — goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003;39(12):1711-7. Abstract

Kennecke H et al. 10 year event-free survival (EFS) in postmenopausal women with early stage breast cancer during the second five years after adjuvant tamoxifen. Breast Cancer Res Treat 2004;Abstract 1049.

Land SR et al. Health-related quality of life in axillary node-negative, estrogen receptornegative breast cancer patients undergoing AC versus CMF chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Res Treat 2004;86(2):153-64. Abstract

Lara R et al. Feasibility of adjuvant chemotherapy with doxorubicin plus docetaxel followed by sequential capecitabine in patients with node positive breast cancer. Proc ASCO 2004;Abstract 782.

Locker GY et al. The time course of bone fractures observed in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2003;Abstract 98.

Loesch D et al. A randomized, multicenter phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer. Breast Cancer Res Treat 2004;Abstract 28.

Loprinzi CL, Ravdin PM. Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians. JNCCN 2003;1(2):189-96. Abstract

Love RR et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003;21(3):453-7. Abstract

Love RR et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002;20(10):2559-66. Abstract

Lyman GH et al. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 2003;21(24):4524-31. Abstract

Martin M et al. Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study. Proc ASCO 2004;Abstract 620.

Martin M et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 2003;Abstract 43.

Muss HB et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005 Mar 2;293(9):1073-81. Abstract

Monnier A et al. What is the role of hormone receptors subgroups on early breast cancer outcome and adjuvant treatment effects? Results of French Adjuvant Study Group data base. Breast Cancer Res Treat 2004;Abstract 1051.

Nowak AK et al. Systematic review of taxanecontaining versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004;5(6):372-80. Abstract

Perez EA. Effect of letrozole versus placebo on bone mineral density in women completing > 5 years (yrs) of adjuvant tamoxifen: NCIC CT MA.17b. Breast Cancer Res Treat 2004;Abstract 404.

Perez EA et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004;22(18):3700-4. Abstract

Rea DW et al. Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT). Proc ASCO 2004;Abstract 595.

Rizel S et al. Doxorubicin 75mg/m² followed by cyclophosphamide, methotrexate, and fluorouracil (A CMF) in the adjuvant treatment of node positive breast cancer: Outcome and toxicity in 136 patients. Proc ASCO 2004;Abstract 849.

Robertson JF, Blamey RW. The use of gonadotrophin- releasing hormone (GnRH) agonists in early and advanced breast cancer in preand perimenopausal women. Eur J Cancer 2003;39(7):861-9. Abstract

Roche H et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 2004;Abstract 27.

Rodenhuis S et al; Netherlands Working Party on Autologous Transplantation in Solid Tumors. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003;349(1):7-16. Abstract

Rodriguez-Lescure A et al. Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial. Proc ASCO 2004;Abstract 596.

Sainsbury R. Ovarian ablation as a treatment for breast cancer. Surg Oncol 2003;12(4):241-50. Abstract

Slanetz PJ et al. Effect of tamoxifen on breast tissue density in premenopausal breast cancer. Breast J 2004;10(1):27-32. Abstract

Smith RE et al. Phase II trial of doxorubicin/ docetaxel doublet for locally advanced and metastatic breast cancer: Results from national surgical adjuvant breast and bowel project trial BP-57. Clin Breast Cancer 2004;5(3):208-15. Abstract

Sverrisdottir A et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004;22(18):3694-9. Abstract

Tallman MS et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003;349(1):17-26. Abstract

Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 2004;100(10):2052-63. Abstract

Thomson CS et al; Scottish Cancer Trials Breast Group; Scottish Cancer Therapy Network. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast 2002;11(5):419-29. Abstract

Thomas E et al. The use of alternate, noncross- resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 2004;22(12):2294-302. Abstract

Tinker A et al. Impact of reduced dose intensity of adjuvant anthracycline based chemotherapy in a population based cohort of stage I-II breast cancers. Proc ASCO 2004;Abstract 552.

Vogel CL et al. The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001. Proc ASCO 2004;Abstract 677.

Winer EP et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive breast cancer: Status report 2004. J Clin Oncol. 2005 Jan 20;23(3):619-29. Abstract

Zander AR et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 2004;15;22(12):2273-83. Abstract